vVARDIS Announces Investment from Apollo

Posted: April 29, 2026
Edited by Dentaltown staff

ZUG, Switzerland—vVARDIS Holding AG announced a minority investment from Apollo-managed funds to support global expansion of its Curodont product platform, a noninvasive treatment for early-stage tooth decay.

The company said the investment will accelerate commercial growth in the U.S. and Europe and expand adoption of its peptide-based formulations designed to support enamel repair without drilling.

Curodont has been used to treat approximately 3 million teeth and is present in nearly 20% of general dental practices in the U.S., according to the company.

vVARDIS said the technology offers clinicians a restorative option for early decay that avoids traditional invasive procedures.

Financial terms were not disclosed. For more information, visit vVARDIS.com or apollo.com.
Views: 10
Sponsors
Townie Perks
Townie® Poll
Is your current software cloud-based?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@dentaltown.com
©2026 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450